A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies
Information source: NIH AIDS Clinical Trials Information Service
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: HIV Infections
Intervention: Delavirdine mesylate (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Pharmacia and Upjohn
Summary
The purpose of this study is to see if it is safe and effective to give delavirdine mesylate
(Rescriptor) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to HIV-infected
children and babies. This study also examines how the body processes Rescriptor when taken
with 2 NRTIs.
Clinical Details
Official title: Phase II Study of the Safety, Tolerance, Pharmacokinetics, and Antiviral Effect of Delavirdine Mesylate (Rescriptor), in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1-Infected Neonates, Infants, and Children
Study design: Treatment
Eligibility
Minimum age: 1 Month.
Maximum age: 15 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria
Patients must have:
- HIV infection.
- Plasma HIV-1 levels greater than 10,000 copies/ml.
Locations and Contacts
Pharmacia & Upjohn, Peapack, New Jersey 07977, United States
Additional Information
Related publications: Willoughby R, Watson D, Welliver R. Early use of RESCRIPTOR (delavirdine) in children with HIV. 39th Intersci Conf Antimicrob Agents Chemother. 1999 Sept 26-29 (abstract no 1995)
Last updated: June 23, 2005
|
